A detailed history of Morgan Stanley transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Morgan Stanley holds 1,815,758 shares of SNDX stock, worth $35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,815,758
Previous 1,664,306 9.1%
Holding current value
$35 Million
Previous $36 Million 20.16%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$19.71 - $24.57 $2.99 Million - $3.72 Million
151,452 Added 9.1%
1,815,758 $43.2 Million
Q4 2023

Feb 13, 2024

BUY
$11.39 - $21.67 $12.7 Million - $24.1 Million
1,114,277 Added 202.59%
1,664,306 $36 Million
Q3 2023

Nov 15, 2023

BUY
$14.52 - $21.77 $1.75 Million - $2.62 Million
120,309 Added 28.0%
550,029 $7.99 Million
Q2 2023

Aug 14, 2023

SELL
$19.35 - $22.31 $12.9 Million - $14.8 Million
-664,124 Reduced 60.71%
429,720 $8.99 Million
Q1 2023

May 15, 2023

BUY
$20.66 - $28.98 $19.5 Million - $27.4 Million
944,475 Added 632.31%
1,093,844 $23.1 Million
Q4 2022

Feb 14, 2023

SELL
$20.64 - $26.24 $189,929 - $241,460
-9,202 Reduced 5.8%
149,369 $3.8 Million
Q3 2022

Nov 14, 2022

SELL
$18.51 - $24.79 $2.46 Million - $3.3 Million
-133,106 Reduced 45.63%
158,571 $3.81 Million
Q2 2022

Oct 27, 2022

SELL
$13.64 - $19.48 $5.54 Million - $7.91 Million
-406,024 Reduced 58.19%
291,677 $5.61 Million
Q2 2022

Aug 15, 2022

SELL
$13.64 - $19.48 $5.54 Million - $7.91 Million
-406,024 Reduced 58.19%
291,677 $5.61 Million
Q1 2022

Oct 27, 2022

BUY
$14.84 - $22.15 $6.03 Million - $8.99 Million
406,024 Added 139.2%
697,701 $12.1 Million
Q1 2022

May 13, 2022

BUY
$14.84 - $22.15 $6.24 Million - $9.31 Million
420,225 Added 151.45%
697,701 $12.1 Million
Q4 2021

Feb 14, 2022

BUY
$15.23 - $22.47 $370,652 - $546,852
24,337 Added 9.61%
277,476 $6.07 Million
Q3 2021

Nov 15, 2021

BUY
$13.87 - $19.8 $3.51 Million - $5.01 Million
253,139 New
253,139 $4.84 Million

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $1.09B
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.